Fidaxomicin
- Generic Name
- Fidaxomicin
- Brand Names
- Dificid, Dificlir
- Drug Type
- Small Molecule
- Chemical Formula
- C52H74Cl2O18
- CAS Number
- 873857-62-6
- Unique Ingredient Identifier
- Z5N076G8YQ
- Background
Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is ...
- Indication
用于治疗艰难梭菌（又名难辨梭状芽孢杆菌）感染相关性腹泻。
- Associated Conditions
- Clostridium Difficile Associated Diarrhea (CDAD)
- Associated Therapies
- -
Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT04070352
- Locations
- 🇺🇸
UPMC, Pittsburgh, Pennsylvania, United States
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
- Conditions
- Interventions
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Summit Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT02784002
- Locations
- 🇺🇸
Laguna Hills, Laguna Hills, California, United States
🇺🇸Ventura, Ventura, California, United States
🇨🇿Pardubice, Pardubice, Czechia
Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection
- Conditions
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 64
- Registration Number
- NCT02743234
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus C, Denmark
A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
- Conditions
- Interventions
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 144
- Registration Number
- NCT02692651
- Locations
- 🇺🇸
St. Joseph Mercy Hospital, Ypsilanti, Michigan, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Optimal Treatment for Recurrent Clostridium Difficile
- Conditions
- Interventions
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 308
- Registration Number
- NCT02667418
- Locations
- 🇺🇸
Southern Arizona VA Health Care System, Tucson, AZ, Tucson, Arizona, United States
🇺🇸VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States
🇺🇸Asheville VA Medical Center, Asheville, NC, Asheville, North Carolina, United States
Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection
- Conditions
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- University of Colorado, Denver
- Registration Number
- NCT02464306
Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)
- Conditions
- Interventions
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02437591
- Locations
- 🇦🇹
Site AT43001, Graz, Austria
🇷🇺Site RU70002, Moscow, Russian Federation
🇵🇱Site PL48002, Warszawa, Poland
Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection
- First Posted Date
- 2015-03-24
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 31
- Registration Number
- NCT02395848
- Locations
- 🇨🇦
Christine Lee, Victoria, BC - British Columbia, Canada
A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 364
- Registration Number
- NCT02254967
- Locations
- 🇭🇺
Site HU36010, Budapest, Hungary
🇬🇷Site GR30007, Athens, Greece
🇬🇷Site GR30004, Athens, Greece
Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients
- Conditions
- Interventions
- First Posted Date
- 2014-08-12
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Astellas Pharma S.A.S.
- Target Recruit Count
- 296
- Registration Number
- NCT02214771
- Locations
- 🇫🇷
Site, Soissons, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.